SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-025080
Filing Date
2024-06-25
Accepted
2024-06-25 15:41:56
Documents
16
Period of Report
2024-06-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 46219
2 ex3-1.htm EX-3.1 11356
3 ex3-2.htm EX-3.2 11448
4 ex10-1.htm EX-10.1 30176
  Complete submission text file 0001493152-24-025080.txt   279928

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE pvct-20240621.xsd EX-101.SCH 3027
6 XBRL LABEL FILE pvct-20240621_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE pvct-20240621_pre.xml EX-101.PRE 22367
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3480
Mailing Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929
Business Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929 (866) 594-5999
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

IRS No.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36457 | Film No.: 241068762
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)